Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

Recordati continues clinical development of BPH Rx

Feb. 13, 1998

Controlled-release oxybutynin to be marketed in Europe by Synthelabo

Feb. 2, 1998

Synaptic develops selective human alpha1A-receptor antagonists

Feb. 2, 1998

RTX enters phase II for urge incontinence

Jan. 27, 1998

FDA accepts RenaGel NDA for filing

Jan. 22, 1998

New urinary incontinence product from Biomatrix cleared for clinical trials

Jan. 12, 1998

Synaptic, Merck & Co. extend BPH research agreement

Jan. 5, 1998

Cephalon describes new indolocarbazoles for prostate disorders

Dec. 30, 1997

NDA filed for extended-release Ditropan formulation

Dec. 29, 1997

Bladder efficacy demonstrated for KATP channel opener

Dec. 19, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...